Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 271-274

  Hughes, Jennifer ^a   Isaakidis, Petros ^a   Andries, Aristomo ^a   Mansoor, Homa ^a   Cox, Vivian ^a   Meintjes, Graeme ^b,c   Cox, Helen ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STAVUDINE; ZIDOVUDINE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANEMIA; BODY MASS; CAUSE OF DEATH; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LOW DRUG DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ADULT; CHILD; COMPLICATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; CHILD; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; HIV INFECTIONS; HUMANS; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937390822     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00188114     Document Type: Letter

References (15)

1. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
2. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
3. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
4. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
5. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
6. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
7. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012; 7: e40781.
8. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014; 18: 441-448.
9. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR-and XDR-TB: an Indian perspective. Eur Respir J 2010; 35: 936-938.
10. Robertson K, Kumwenda J, Supparatpinyo K, et al. A multinational study of neurological performance in antiretroviral therapy-naive HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol 2011; 17: 438-447.
11. Frippiat F, Bergiers C, Michel C, et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53: 1114-1115.
12. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009; 4: e7186.
13. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
14. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
15. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.